Healthcare legislation boosts future of cancer care services

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 4
Volume 19
Issue 4

Oncology fared well under the new healthcare reform legislation without cuts to the core businesses of medical oncology, radiation oncology, office-administered drugs, and PET/PET-CT imaging.

BALTIMORE-Oncology fared well under the new healthcare reform legislation without cuts to the core businesses of medical oncology, radiation oncology, office-administered drugs, and PET/PET-CT imaging, according to a presenter at the 2010 Association of Community Cancer Centers meeting.

The new legislation will spend $940 billion over ten years to expand private insurance coverage and expand the privately insured patient population including those who require cancer care, said Matt Brow, vice president of government relations and public policy for US Oncology, based in the Woodlands, Tex.

Mr. Brow pointed out some of the provisions that directly affect oncology care:

Practices can voluntarily participate in accountable care organizations (ACOs) that will manage and coordinate care across settings. Lower cost or the use of equally effective regimens will be rewarded. ACOs can consist of physician groups, networks of physician groups, and joint ventures between a hospital and physicians.
The CMS Innovation Center, a testing ground for new payment models, will align nationally recognized, evidence-based guidelines of cancer care with Medicare payment incentives for treatment planning and follow-up care for Medicare beneficiaries.
Insurance company coverage of routine costs associated with participation in a clinical trial, which may increase trial participation.
New fees on medical device manufacturers such as higher costs for such equipment as linear accelerators.

Source: "Healthcare Reform: How Does Oncology Fare?,"

www.accc-cancer.org

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.